

CLAIMS

What is claimed is:

1. A method of treating a human with neurological disorders comprising administering therapeutically effective doses of uridine or a uridine source.
2. The method according to claim 1 wherein said therapeutically effective dose of uridine or a uridine source is administered for at least one day.
3. The method according to claim 1 wherein said neurological disorders are memory disorders.
4. The method according to claim 3 wherein said memory disorders comprise memory decline associated with brain aging.
5. The method according to claim 3 wherein said memory disorders are selected from the group comprising of Pick's disease, Lewy Body disease, and/or dementias like Huntington's disease and AIDS dementia.
6. The method according to claim 1 wherein said neurological disorders are cognitive dysfunctions comprising lack of attention, alertness, concentration, focus, or dyslexia.
7. The method according to claim 1 wherein said neurological disorders are emotional disorders comprising mania, depression, stress, panic, anxiety, dysthemia, psychosis, seasonal effective disorders and bipolar disorders.
8. The method according to claim 1 wherein said neurological disorders are selected from the group consisting of ataxia or Friedreich's ataxia.

- 9 The method according to claim 1 wherein said neurological disorders are movement disorders comprising tardive dyskinesia.
- 10 The method according to claim 1 wherein said neurological disorders are cerebral thrombosis, ischemia, and related cerebrovascular diseases resulting from hypoxia.
- 5 11. The method according to claim 1 wherein said neurological disorders are behavioral and neurological syndromes.
12. The method according to claim 11 wherein said behavioral and neurological syndromes comprise those seen after brain trauma, spinal cord injury and/or anoxia.
13. The method according to claim 1 wherein said neurological disorders are peripheral nervous system disorders comprising neuromuscular disorders like myasthenia gravis, the post-polio syndrome, and muscular dystrophies.
- 10 14. The method according to claim 1 wherein said uridine is combined with pharmaceutically acceptable source of uridine.
- 15 15. The method according to claim 1 wherein said uridine or pharmaceutically acceptable source of uridine is administered in dosages of between 100 mg and 20 grams per day.
16. A method of treating a human with neurological disorders comprising administering therapeutically effective dose of at least uridine or a uridine source and other compounds.
17. The method according to claim 16 wherein said neurological disorders are memory disorders.
- 20 18. The method according to claim 17 wherein said memory disorders comprise memory decline associated with brain aging.

19. The method according to claim 17 wherein said memory disorders are selected from the group comprising Pick's disease, Lewy Body disease, and/or dementias like Huntington's disease and AIDS dementia.
20. The method according to claim 16 wherein said neurological disorders are cognitive dysfunctions comprising lack of attention, alertness, concentration, focus, or dyslexia.
21. The method according to claim 16 wherein said neurological disorders are emotional disorders comprising mania, depression, stress, panic, anxiety, dysthemia, psychosis, seasonal effective disorders and bipolar disorders.
22. The method according to claim 16 wherein said neurological disorders are selected from the group consisting of ataxia or Friedreich's ataxia.
23. The method according to claim 16 wherein said neurological disorders are movement disorders comprising tardive dyskinesia.
24. The method according to claim 16 wherein said neurological disorders are cerebral thrombosis, ischemia, and related cerebrovascular diseases resulting from hypoxia.
25. The method according to claim 16 wherein said neurological disorders are behavioral and neurological syndromes.
26. The method according to claim 25 wherein said behavioral and neurological syndromes comprise those seen after brain trauma, spinal cord injury and/or anoxia.
27. The method according to claim 16 wherein said neurological disorders are peripheral nervous system disorders comprising neuromuscular disorders like myasthenia gravis, the post-polio syndrome, and muscular dystrophies.
28. The method according to claim 16 wherein said neurological disorders selected from the

group consisting of schizophrenia and Parkinson's disease.

29. The method according to claim 16 wherein said other compound is choline.

30. The method according to claim 16 wherein said other compounds are choline salt or stearate selected from the group consisting of choline chloride, choline bitartrate, choline stearate or mixtures thereof.

31. The method according to claim 16 wherein said other compounds are choline precursors selected from the group consisting of sphingomyelin, cytidine-diphospho-choline or citicoline or CDP-choline, an acylglycerophosphocholine, e.g., lecithin, lysolecithin, glycerophosphatidylcholine, fatty acids, or mixtures thereof.

32. The method as in ^{claim 29} ~~one of claims 29-31~~ wherein a choline level of at least about 20-30 nanomoles and usually between 10 and 50 nanomoles is attained in patient's blood or brain.

33. The method according to claim 16 wherein said other compounds are uridine phosphorylase inhibitors comprising benzyl barbiturate or derivatives thereof.

34. The method according to claim 16 wherein said other compounds are uridine secretion inhibiting compounds comprising dilazep or hexobendine.

35. The method according to claim 16 wherein said other compounds are uridine renal transport competitors selected from the group consisting of L-uridine, L-2',3'-dideoxyuridine, and D-2',3'-dideoxyuridine.

36. The method according to claim 16 wherein said other compound is a mixture of compounds from ^{claim 29} ~~any one of claims 29-31 or 33-35~~.

37. The method according to claim 16 wherein said uridine or a uridine source are

~~administered in dosages of between 10 mg and 10 grams per day.~~

38. The method according to claim 16 wherein said therapeutically effective dose of uridine or a uridine source in combination with other drugs is administered for at least one day.

add
C1

Case 1:13-cv-00000-00000